



## **BioInvent's new Chief Executive Officer, Martin Welschof, takes office on 1 September**

**Lund, Sweden – 31 August, 2018** – BioInvent International AB (OMXS: BINV) announces today that Martin Welschof will officially take office as Chief Executive Officer on 1 September. Björn Frenhéus, acting CEO of BioInvent since 1 January, 2018, will resume his fulltime role of Chief Scientific Officer. The Company first announced Dr. Welschof's appointment on 12 April 2018.

Martin Welschof, said: "Albeit it at some remove, during the months of transition I got to know the Company quite well, and have been impressed by the commitment and know-how throughout the organization. I am very keen to start in a fulltime capacity, and work with the management team and all other colleagues to further hone the Company's strategy, build the development pipeline, and maximize the opportunities of BioInvent's powerful antibody platform."

Leonard Kruimer, Chairman of BioInvent's Board of Directors, said: "The Board looks forward to working with Martin and the executive team to accelerate BioInvent's focus on immuno oncology."

### **About BioInvent**

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programs are BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia, and TB-403, in cooperation with Oncurios, currently in Phase I/II for medulloblastoma. BioInvent has a promising pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells, and tumour-associated myeloid cells. The Company has a strategic research collaboration with Pfizer Inc., and also works with leading academic institutions, such as the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent has partnerships with Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and generates revenues from the manufacturing for third parties of antibodies for research through to late-stage clinical trials. More information is available at [www.bioinvent.se](http://www.bioinvent.se)

### **For further information, please contact:**

Martin Welschof, CEO  
+46 (0)46 286 85 50  
[martin.welschof@bioinvent.com](mailto:martin.welschof@bioinvent.com)

Hans Herklots, LifeSci Advisors  
+41 79 598 71 49  
[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)

### **BioInvent International AB (publ)**

Co. reg. No. 556537-7263  
Visiting address: Sölvegatan 41  
Mailing address: 223 70 LUND  
Phone: +46 (0)46 286 85 50  
[www.bioinvent.com](http://www.bioinvent.com)

*The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment,*

*associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.*